NO980656L - Analogifremgangsmåte for fremstilling av et gjenformet menneskeantistoff eller et gjenformet menneskeantistoff-fragment til å behandle kreft - Google Patents

Analogifremgangsmåte for fremstilling av et gjenformet menneskeantistoff eller et gjenformet menneskeantistoff-fragment til å behandle kreft

Info

Publication number
NO980656L
NO980656L NO980656A NO980656A NO980656L NO 980656 L NO980656 L NO 980656L NO 980656 A NO980656 A NO 980656A NO 980656 A NO980656 A NO 980656A NO 980656 L NO980656 L NO 980656L
Authority
NO
Norway
Prior art keywords
human antibody
reshaped human
reshaped
preparing
treat cancer
Prior art date
Application number
NO980656A
Other languages
English (en)
Other versions
NO980656D0 (no
Inventor
Martine Elisa Verhoeyen
Original Assignee
Unilever Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898926045A external-priority patent/GB8926045D0/en
Priority claimed from GB909019552A external-priority patent/GB9019552D0/en
Publication of NO980656L publication Critical patent/NO980656L/no
Application filed by Unilever Nv filed Critical Unilever Nv
Publication of NO980656D0 publication Critical patent/NO980656D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Fireproofing Substances (AREA)
  • Paper (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Dental Preparations (AREA)

Abstract

Et gjenformet menneskeantistoff eller gjenformet menneske- antistoff-fragment med spesifisitet for human placental alkali- fosfatase (PLAP) fremstilles ved å overføre de komplementæritets- bestemmende regioner (CDR'er) fra et musedyrs anti-PLAP hybridoma cellelinje H17E2 i et menneskes antistoff-variabelt-områderamme- verk. Det gjenformete molekyl kan brukes ved behandling av kreft.
NO980656A 1989-11-17 1998-02-16 Analogifremgangsmåte for fremstilling av et gjenformet menneskeantistoff eller et gjenformet menneskeantistoff-fragment til å behandle kreft NO980656D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898926045A GB8926045D0 (en) 1989-11-17 1989-11-17 Specific binding agents
GB909019552A GB9019552D0 (en) 1990-09-07 1990-09-07 Specific binding agents
PCT/GB1990/001755 WO1991007500A1 (en) 1989-11-17 1990-11-14 Specific binding agents

Publications (2)

Publication Number Publication Date
NO980656L true NO980656L (no) 1992-05-15
NO980656D0 NO980656D0 (no) 1998-02-16

Family

ID=26296218

Family Applications (2)

Application Number Title Priority Date Filing Date
NO921941A NO303066B1 (no) 1989-11-17 1992-05-15 Gjenformet menneskeantistoff med spesifisitet for human placental alkalisk fosfatase eller fragment derav
NO980656A NO980656D0 (no) 1989-11-17 1998-02-16 Analogifremgangsmåte for fremstilling av et gjenformet menneskeantistoff eller et gjenformet menneskeantistoff-fragment til å behandle kreft

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO921941A NO303066B1 (no) 1989-11-17 1992-05-15 Gjenformet menneskeantistoff med spesifisitet for human placental alkalisk fosfatase eller fragment derav

Country Status (16)

Country Link
EP (1) EP0429242B1 (no)
JP (1) JPH05501357A (no)
KR (2) KR970007783B1 (no)
AT (1) ATE123815T1 (no)
AU (1) AU652923B2 (no)
BG (1) BG60687B1 (no)
CA (1) CA2066670A1 (no)
DE (1) DE69020112T2 (no)
DK (1) DK0429242T3 (no)
ES (1) ES2075169T3 (no)
FI (1) FI922220L (no)
GR (1) GR3017407T3 (no)
HU (1) HUT64600A (no)
NO (2) NO303066B1 (no)
RO (1) RO110262B1 (no)
WO (1) WO1991007500A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
JP5297742B2 (ja) * 2008-09-26 2013-09-25 株式会社青木科学研究所 金型用粉体含有油性潤滑剤、これを用いた静電塗布方法、及び静電塗布装置
ES2975747T3 (es) * 2015-11-30 2024-07-12 Univ California Administración de carga útil específica de tumor y activación inmunitaria utilizando un anticuerpo humano que se dirige a un antígeno de superficie celular de tumor altamente específico
EP3806894A4 (en) 2018-06-12 2022-06-08 Promab Biotechnologies, Inc. PLAP-CAR EFFECTOR CELLS
CA3209579A1 (en) 2021-01-27 2022-08-04 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof
IL311570A (en) * 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells with common expression chain and logic gate systems
CN114014933B (zh) * 2021-11-17 2023-05-02 福州迈新生物技术开发有限公司 抗plap蛋白单克隆抗体、细胞系及其制备方法和应用
WO2025048716A1 (en) * 2023-08-25 2025-03-06 Axcynsis Therapeutics Pte. Ltd. Anti-alpp/alppl2 antibodies, antibody-drug conjugates, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product

Also Published As

Publication number Publication date
EP0429242A2 (en) 1991-05-29
DE69020112T2 (de) 1995-11-02
EP0429242A3 (en) 1991-06-05
NO921941L (no) 1992-05-15
HUT64600A (en) 1994-01-28
EP0429242B1 (en) 1995-06-14
JPH05501357A (ja) 1993-03-18
FI922220A7 (fi) 1992-05-15
BG96346A (bg) 1993-12-24
RO110262B1 (ro) 1995-11-30
DE69020112D1 (de) 1995-07-20
FI922220A0 (fi) 1992-05-15
CA2066670A1 (en) 1991-05-18
FI922220L (fi) 1992-05-15
ATE123815T1 (de) 1995-06-15
KR920703837A (ko) 1992-12-18
WO1991007500A1 (en) 1991-05-30
KR970007783B1 (ko) 1997-05-16
BG60687B1 (bg) 1995-12-29
NO303066B1 (no) 1998-05-25
DK0429242T3 (da) 1995-10-16
NO980656D0 (no) 1998-02-16
HU9201619D0 (en) 1992-08-28
AU6736990A (en) 1991-06-13
KR970007782B1 (ko) 1997-05-16
NO921941D0 (no) 1992-05-15
AU652923B2 (en) 1994-09-15
GR3017407T3 (en) 1995-12-31
ES2075169T3 (es) 1995-10-01

Similar Documents

Publication Publication Date Title
DK0483961T3 (da) Specifikke bindemidler
NO980656D0 (no) Analogifremgangsmåte for fremstilling av et gjenformet menneskeantistoff eller et gjenformet menneskeantistoff-fragment til å behandle kreft
AU2975697A (en) Human monoclonal antibodies to the hepatitis b surface antigen
DE3584872D1 (de) Verfahren zur herstellung von monoklonalen antikoerpern gegen hbsag.
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
Jennings et al. Functional analysis of the effect of monoclonal antibodies on monkey liver phenylalanine hydroxylase
Yuan et al. Human pancreatic cancer-associated antigens detected by murine monoclonal antibodies
Rea et al. A novel method for controlling the pepsin digestion of antibodies
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
SU1637670A3 (ru) Способ определени @ -амилазы поджелудочной железы
DE3787239T2 (de) Komplementabhängiger zytolytischer monoklonaler Antikörper gegen Trichomonas vaginalis und seine therapeutische und diagnostische Verwendung.
EP0262571A2 (de) Neue monoklonale Antikörper gegen IFN-omega, Verfahren zu ihrer Herstellung und deren Verwendung zur Reinigung sowie zum Nachweis von IFN-omega
JPH0753756B2 (ja) 抗ヘパラン硫酸モノクロ−ン抗体及びこれを用いるヘパラン硫酸の検出方法
Johnston et al. Comparison of paraquat-specific murine monoclonal antibodies produced by in vitro and in vivo immunization
US4803167A (en) Monoclonal antidigoxtin antibodies
JP3091974B2 (ja) ８―ハイドロキシ―２’―デオキシグアノシンのモノクローナル抗体及びその製造法並びにモノクローナル抗体を生産するハイブリッド細胞
SU1049811A1 (ru) Способ определени ингибирующих свойств плазмы крови
DE3650570D1 (de) Verfahren und Reagenz zur Bestimmung des Follikel stimulierenden Hormons sowie hierzu geeignete monoklonale Antikörper
ZUSMAN et al. Isolation of tumor-associated protein from sera of colon tumor-bearing rats using polyclonal antibodies entrapped in gel fiberglass columns
JPH0379994B2 (no)
RU2049818C1 (ru) Штамм гибридных культивируемых клеток мыши mus musculus l., испольуемый для получения моноклональных антител к дигоксину
JPH0459880B2 (no)
RU93033872A (ru) Связывающие агенты, антитела, клетки плазмиды, применение плазмид, днк, вариабельные области антител, композиция, применение связующих агентов
AT389318B (de) Neue hybridomzellinien, welche neue monoklonale antikoerper gegen ifn-omega produzieren, verfahren zu ihrer herstellung und die verwendung der neuen monoklonalen antikoerper zur reinigung sowie zum nachweis von ifn-omega
HIRAMATSU Renal disease and streptococcal infection II. Study of streptococcal infection on IgA nephropathy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application